Shanghai Bojin Medical Instrument Co., Ltd.  

Follow0

Established in 1993 and headquartered in Shanghai, Bojin, as an advanced orthopedic equipment manufacturer and solutions provider, Bojin focuses on the development and marketing of orthopedic-purpose motor products, X-ray imagescopes, treatment apparatus, and supporting surgical tools/parts. It has more than one hundred types of orthopedic products under 8 series, which have received QC certification of 3C, ISO9001, ISO13485, CE of the EU, and FDA Registry 3008787426. Its mission is to satisfy the needs of patients and medical care with innovative high-tech products and therefore become a promoter of people's orthopedic health. It has built a healthy sales and services network thanks to its 200 dedicated employees in the marketing companies or teams in more than 4countries and regions across North America, Europe and Asia. Its products are used in more than 125 countries and, in particular, in more than 20000 Chinese medical institutions 70% of which are 3A-rated hospitals. Bojin respects professionalism and talents and values core technology R&D. Its R&D team accounts for up to 20% of its staff, for it is fully aware that its top-notch professionals provide for the healthy operation of the company, the steady supply of high-quality medical equipment and comprehensive services for its global customers. Its innovation in products and solutions reduce social medical costs and therefore lessen the financial burden of patients. In the spirit of valuing life and health, Bojin, with a strong sense of social responsibility, are dedicated to innovating technology and upgrading product quality, thus ultimately helping improve the health of larger population. Its development is, as always, dependent upon technological innovation, common endeavor of the staff, and constant improvement of management philosophy. Each step forward has witnessed the staff's resilience and entrepreneurship, which, in turn, promotes the company's development and fortifies the staff's confidence in the company's prospect. [Read More]